Amgen (AMGN)'s First Quarter 2013 Revenues Increased 5 Percent to $4.2 Billion and Adjusted Earnings Per Share (EPS) Increased 22 Percent to $1.96
4/24/2013 6:36:30 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
THOUSAND OAKS, Calif., April 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2013. Key results for the quarter include:
-- Total revenues increased 5 percent to $4,238 million, with 6 percent
product sales growth driven by Enbrel(R) (etanercept), XGEVA(R)
(denosumab) and Prolia(R) (denosumab).
Help employers find you! Check out all the jobs and post your resume.
comments powered by